Demo
ADMA Nasdaq· ADMA Biologics Inc.
FundamentalsNews digest Peer analysis
Login
ADMA Nasdaq· ADMA Biologics Inc.
Earnings report Q4 2023

ADMA Biologics Reports Strong Revenue Growth in Latest Quarter

Segments of Revenue

ADMA Biologics reported total revenues of $258.2 million in the latest quarter. The breakdown of revenue by segment is as follows:

  • ADMA BioManufacturing: $249.7 million
  • Plasma Collection Centers: $8.3 million
  • Corporate: $0.1 million

Strengths

ADMA Biologics demonstrated impressive revenue growth in the latest quarter, with total revenues increasing by 67% compared to the same period last year. The significant growth was primarily driven by the strong performance of the ADMA BioManufacturing segment, which accounted for the majority of the company's revenue. This segment saw a substantial increase in revenue from $144.1 million in the previous year to $249.7 million in the latest quarter. The management attributed this growth to increased demand for specialty biologics used in the treatment of immunodeficient patients.

Challenges

Despite the overall positive revenue growth, ADMA Biologics faced challenges in its Plasma Collection Centers segment. This segment reported a decrease in revenue from $9.9 million in the previous year to $8.3 million in the latest quarter. The management highlighted that this decline was due to certain operational challenges faced by the Plasma Collection Centers, which impacted their revenue generation.

Noteworthy

It is worth mentioning that ADMA Biologics reported a net loss of $28.2 million in the latest quarter. This loss was primarily driven by significant expenses, including interest and other expenses, as well as a loss on extinguishment of debt. The company also incurred capital expenditures of $4.8 million and depreciation and amortization expenses of $8.3 million during the quarter.

Summary

ADMA Biologics delivered a strong performance in terms of revenue growth in the latest quarter, driven by the robust performance of its ADMA BioManufacturing segment. The company's total revenues increased by 67% compared to the same period last year. However, challenges were observed in the Plasma Collection Centers segment, which experienced a decline in revenue. ADMA Biologics reported a net loss for the quarter, primarily due to significant expenses. Overall, the company's revenue growth highlights its success in meeting the demand for specialty biologics used in the treatment of immunodeficient patients.

Source documents

Form 10-K  filed on Feb 28, 2024
63 pages scanned

Reference data

Company financials Q4 revenue 73.9M
Analyst estimates Q4 EPS missed by -480.00%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.